Request Free Sample ×
India Transthyretin Amyloidosis Market Research Report - Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

India Transthyretin Amyloidosis Market

ID: MRFR/HC/54253-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026

India Transthyretin Amyloidosis Market Research Report By Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), By Gender (Male, Female), By Treatment (Small Molecule Treatment) and By End-User (Ambulatory Surgical Center, Clinics) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

India Transthyretin Amyloidosis Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Food, Beverages & Nutrition, BY Drug (USD Million)
  49.     4.1.1 Inotersen
  50.     4.1.2 Partisiran
  51.     4.1.3 Tafamidis
  52.     4.1.4 Others
  53.   4.2 Food, Beverages & Nutrition, BY Indication (USD Million)
  54.     4.2.1 Wild type ATTR Amyloidosis
  55.     4.2.2 Hereditary ATTR Amyloidosis
  56.   4.3 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
  57.     4.3.1 Retail pharmacy
  58.     4.3.2 Hospital pharmacy
  59.     4.3.3 Online pharmacy
  60.   4.4 Food, Beverages & Nutrition, BY Treatment (USD Million)
  61.     4.4.1 Small molecule treatment
  62.     4.4.2 Tafamidis
  63.     4.4.3 Diflunisal
  64.     4.4.4 RNAi Therapy
  65.     4.4.5 Organ Transplantation
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 Alnylam Pharmaceuticals (US)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Pfizer (US)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 Bristol-Myers Squibb (US)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Ionis Pharmaceuticals (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 Eisai Co., Ltd. (JP)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Amgen Inc. (US)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 Teva Pharmaceutical Industries Ltd. (IL)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 Horizon Therapeutics (IE)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.   5.3 Appendix
  131.     5.3.1 References
  132.     5.3.2 Related Reports
  133. 6 LIST OF FIGURES
  134.   6.1 MARKET SYNOPSIS
  135.   6.2 INDIA MARKET ANALYSIS BY DRUG
  136.   6.3 INDIA MARKET ANALYSIS BY INDICATION
  137.   6.4 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  138.   6.5 INDIA MARKET ANALYSIS BY TREATMENT
  139.   6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
  140.   6.7 RESEARCH PROCESS OF MRFR
  141.   6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
  142.   6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  143.   6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  144.   6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
  145.   6.12 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 (% SHARE)
  146.   6.13 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 TO 2035 (USD Million)
  147.   6.14 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
  148.   6.15 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Million)
  149.   6.16 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  150.   6.17 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  151.   6.18 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
  152.   6.19 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
  153.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  154. 7 LIST OF TABLES
  155.   7.1 LIST OF ASSUMPTIONS
  156.     7.1.1
  157.   7.2 India MARKET SIZE ESTIMATES; FORECAST
  158.     7.2.1 BY DRUG, 2025-2035 (USD Million)
  159.     7.2.2 BY INDICATION, 2025-2035 (USD Million)
  160.     7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  161.     7.2.4 BY TREATMENT, 2025-2035 (USD Million)
  162.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  163.     7.3.1
  164.   7.4 ACQUISITION/PARTNERSHIP
  165.     7.4.1

India Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Drug (USD Million, 2025-2035)

  • Inotersen
  • Partisiran
  • Tafamidis
  • Others

Food, Beverages & Nutrition By Indication (USD Million, 2025-2035)

  • Wild type ATTR Amyloidosis
  • Hereditary ATTR Amyloidosis

Food, Beverages & Nutrition By Distribution Channel (USD Million, 2025-2035)

  • Retail pharmacy
  • Hospital pharmacy
  • Online pharmacy

Food, Beverages & Nutrition By Treatment (USD Million, 2025-2035)

  • Small molecule treatment
  • Tafamidis
  • Diflunisal
  • RNAi Therapy
  • Organ Transplantation

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓